ALS breakthrough

American researchers are one step closer to creating a new treatment for ALS or Lou Gehrig’s disease.

It’s the most common cause of neurological death in Canada, affecting over 3,000 people a year and another 30,000 a year in the U.S.

Researchers from Brigham and Women’s Hospital have discovered that changes in monocytes, a type of white blood cell, are a bio-marker for ALS.

One of the study’s authors say looking at white blood cells will open the door for new therapeutic targets for ALS and other diseases.